Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roprostin N01 for secondary prevention of chemotherapy-induced thrombocytopenia in gastrointestinal adenocarcinoma
ChiCTR2500098819Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Shanxi Medical University
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romiplostim in chemotherapy-induced thrombocytopenia (CIT), sponsored by First Affiliated Hospital of Shanxi Medical University. Primary endpoint: Efficacy of receiving roprostin N01 for secondary prevention. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on ChiCTR2500098819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098819.